This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Osteoporosis
  • /
  • Zoledronic Acid Use and Risk of Cognitive Decline ...
Journal

Zoledronic Acid Use and Risk of Cognitive Decline among Elderly Women and Men with Osteoporosis.

Read time: 1 mins
Published:25th Mar 2020
Author: Tasci I, Safer U, Cintosun U, Bozoglu E, Naharci I, Aydogdu A et al.
Ref.:Endocr Metab Immune Disord Drug Targets. 2015 Nov 3.
DOI:10.2174/1871530315666151104115829

Objectives: Bisphosphonates are the first line treatment options in the prevention and treatment of osteoporosis among elderly women or men. Age associated cognitive decline may increase due to adverse effects of medications. The aim of the present study was to observe the course of cognitive skills in elderly subjects treated with a bisphosphonate.

Materials and Methods: This prospective study enrolled 120 community-dwelling, non-demented women and men with osteoporosis aged 65 and older who were treated with first-ever zoledronic acid. Mini mental state examination (MMSE) was measured along with geriatric depression scale (GDS) measurement, clock drawing test (CDT), and other clinical and laboratory evaluations that could affect cognition at baseline and 12 months. The primary outcome was at least one point decrease in the final MMSE score at one year.

Results: Scores of MMSE (28.29±2.17 and 28.23±2.37, p=0.681), GDS (3.24±2.88 and 2.96±2.88, p=0.062) and CDT (3.69±0.68 and 3.75±0.60, p=0.268) did not change after zoledronic acid infusion at one year. Education in years and presence of newly started medicines with anticholinergic properties was independently associated with at least one point reduction in MMSE score [odds ratio: 3.07 (%95 confidence interval: 1.00–9.44)].

Conclusions: Among elderly woman and men with osteoporosis, cognitive functions remained stable 12 months after the administration of first-ever zoledronic acid.

 

Read abstract on library site